BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

Core Insights - BioMarin Pharmaceutical Inc. announced positive results from its phase 3 Pegasus trial for its drug Palynziq (pegvaliase) aimed at treating patients with phenylketonuria (PKU) [2] Company Overview - BioMarin Pharmaceutical Inc. is focused on developing therapies for rare genetic diseases, with Palynziq being a significant product in its pipeline [2] Industry Context - The success of the Pegasus trial may enhance BioMarin's position in the biotech sector, particularly in the treatment of PKU, which is a rare metabolic disorder [2]